应用AGREE II工具评估当前肝细胞癌切除指南
该研究旨在用AGREE II工具评估现有肝细胞癌(HCC)切除指南的方法学质量。检索共纳入22部临床实践指南,结果显示仅5部在总体评估中超过70%分,10部低于50%分,仅3部被认为无需修改即可适用,结论为HCC手术管理指南的方法学质量普遍较差。
要点
- 22部HCC切除指南中仅5部总体评估得分超过70%。
- 22部中10部总体评估得分低于50%,方法学质量低。
- 仅3部指南被认为无需修改即可适用。
核心结论
- 肝细胞癌手术管理指南的方法学质量普遍较差。
- 未来指南制定应参考AGREE II工具。
- 基于高质量证据的指南可改善患者分层和个体化治疗策略。
研究设计与样本
- 研究采用AGREE II工具(2013版)评估肝细胞癌切除相关临床实践指南和共识的方法学质量。
- 检索Cochrane、Medline、Google Scholar和Embase数据库,采用PRISMA标准和自由文本检索。
- 共纳入22部临床实践指南。
- 总体评估项目得分≥80%的指南被认为无需修改即可适用。
主要发现
- 22部指南中5部在总体评估中超过70%分。
- 22部中11部在适应证、禁忌证、副作用、关键推荐、技术方面、透明度和卫生经济学方面存在不足。
- 22部中10部得分低于50%,显示指南方法学和总体质量低。
- 仅3/22部临床实践指南被认为无需修改即可适用。
关键数值与推荐
- 总体评估项目得分≥80%的指南被认为无需修改即可适用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Numerous guidelines for the management of hepatocellular carcinoma (HCC) have been developed. The Appraisal of Guidelines for Research & Evaluation (AGREE II) is the only validated instrument to assess the methodological quality of guidelines. We aim to appraise the methodological quality of existing guidelines for the resection of HCC using the AGREE II instrument. METHODS: Cochrane, Medline, Google Scholar and Embase were searched using both PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and free text. The assessment of the included clinical practice guidelines and consensuses were performed using the AGREE II instrument, version 2013. Guidelines with a score ⩾80% for the overall appraisal item were considered as applicable without modifications. RESULTS: Literature searches identified 22 clinical practice guidelines. Five out of 22 guidelines passed the 70% mark on overall assessment, 11 out of 22 had shortcomings on indications, contraindications, side effects, key recommendations, technical aspects, transparency and health economics. Ten of 22 scored below the 50% mark showing that the guideline had low methodological and overall quality. Only 3/22 clinical practice guidelines were considered applicable without modifications. CONCLUSIONS: The methodological quality of guidelines for the surgical management of HCC is generally poor. Future guideline development should be informed by the use of the AGREE II instrument. Guidelines based upon high quality evidence could improve stratification of patients and individualized treatment strategies. Lay summary: The methodology of clinical practice guidelines for resection for hepatocellular carcinoma (HCC) evaluated with the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument is generally poor. However, there are some clinical practice guidelines that are based upon higher quality evidence and can form the framework within which patients with HCC can be selected for surgical resection. Future guideline development should be informed by the use of the AGREE II instrument.
引用
- Gavriilidis P, Roberts KJ, Askari A, et al. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. J Hepatol. 2017. PMID: 28690176. doi:10.1016/j.jhep.2017.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。